NEW YORK (GenomeWeb News) – Vermillion said that it has received a non-compliance warning letter from the Nasdaq Stock Market because it has failed to maintain a minimum bid price of $1 over the past 30 business days.
 
Vermillion was previously called Ciphergen. Trading opened for the company under the symbol "VMRL" on August 27, when it was trading at just over $.80 a share.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.